Todd C. Brady - 03 Jun 2026 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Reporting relationship: President and CEO, Director
Issuer ticker: ALDX
Reported as of: 03 Jun 2026
Net transaction value: +$418,450
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:19:07 UTC
Prior SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Todd C. Brady

Key filing fact

Todd C. Brady filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 05 Jun 2026.

Key facts

This page summarizes Todd C. Brady's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 16:19.

Change

Previous filing in this sequence was filed on 31 Mar 2026.
Current net transaction value: +$418,450.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001579179 Primary reporting owner

Brady Todd C

Relationship: President and CEO, Director
Address: C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON
Signature: /s/ Todd C. Brady
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALDX transaction

Common Stock

Purchase

Transaction value: $418,450
Shares: +250,000
Change %: +17%
Price: $1.67
Shares after: 1,721,298
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.